Ipratropium Enfants Unidose Teva

Ipratropium Bromide, the active ingredient in Ipratropium Enfants Unidose Teva, is an anticholinergic (muscarinic antagonist) presented as a unit‑dose inhalation preparation for inhalation use. It provides bronchodilation by blocking muscarinic receptors in the airway smooth muscle, and is indicated for the treatment of bronchospasm associated with asthma in children and chronic obstructive pulmonary disease.

GNH USA supplies Ipratropium Enfants Unidose Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on meeting the needs of pediatric respiratory care in the European market.

Ipratropium bromide is a bronchodilator that acts on muscarinic receptors to relieve airway narrowing in several respiratory conditions.

- Asthma (children): reduces bronchoconstriction and improves breathing in pediatric patients. - Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation to ease airflow limitation. - Bronchospasm: rapidly relaxes airway smooth muscle during acute episodes.

Adverse reactions may occur with inhaled ipratropium bromide. Most are mild and reversible, but rare serious events have been reported.

Common Side Effects: - Dry mouth: reduced salivation after inhalation. - Cough: transient irritation of the airway. - Throat irritation: mild soreness or discomfort. - Hoarseness: temporary voice changes. - Nasal congestion: mild blockage of nasal passages. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of airway obstruction. - Allergic reactions: rash, itching, or swelling. - Angioedema: swelling of lips, tongue, or face. - Severe respiratory distress: difficulty breathing requiring medical attention. - Cardiac arrhythmias: rare irregular heartbeats. - Vision changes: blurred vision or eye irritation.

Use ipratropium bromide with caution in specific clinical situations and follow recommended handling procedures.

- Pregnancy: discuss potential risks with a healthcare professional before use. - Breastfeeding: consider possible drug transfer to infant; consult a physician. - Pediatric use: ensure proper technique with the unidose device for children. - Pre‑existing glaucoma: monitor intra‑ocular pressure as anticholinergic effects may exacerbate. - Cardiovascular disease: observe for any changes in heart rate or rhythm. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ipratropium bromide may interact with other medications that affect cholinergic pathways or respiratory function.

Major Interactions (Avoid): - Beta‑agonists combined with high‑dose anticholinergics: may increase risk of cardiovascular side effects. - Tricyclic antidepressants: additive anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- Other inhaled bronchodilators (e.g., albuterol): monitor for synergistic bronchodilation. - Antihistamines with anticholinergic properties: watch for excessive dryness. - Muscarinic antagonists (e.g., tiotropium): assess cumulative anticholinergic effect. - MAO inhibitors: potential for increased cholinergic side effects. - Theophylline: monitor for altered respiratory response.